Eli Lilly and Company $LLY Shares Sold by Blodgett Wealth Advisors LLC

Key Points

• Blodgett Wealth Advisors LLC has reduced its stake in Eli Lilly by 8.3%, now holding 4,607 shares, valued at approximately $3,591,000.
• Eli Lilly reported $6.31 EPS for the last quarter, exceeding analysts' expectations of $5.59, with revenues increasing 37.6% year-over-year.
• The company's latest quarterly dividend was $1.50 per share, yielding 0.8%, with a dividend payout ratio of 39.22%.

Blodgett Wealth Advisors LLC cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 8.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,607 shares of the company's stock after selling 415 shares during the quarter. Eli Lilly and Company makes up approximately 2.8% of Blodgett Wealth Advisors LLC's investment portfolio, making the stock its 8th largest position. Blodgett Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $3,591,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Duquesne Family Office LLC raised its stake in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after buying an additional 32,640 shares during the period. Corient IA LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $570,000. LS Investment Advisors LLC raised its stake in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after buying an additional 40 shares during the period. Cutter Capital Management LP purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $14,866,000. Finally, Prism Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $207,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $763.59 on Wednesday. The business has a 50-day moving average of $740.25 and a 200 day moving average of $774.23. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.86. The stock has a market capitalization of $722.71 billion, a price-to-earnings ratio of 49.91, a price-to-earnings-growth ratio of 1.04 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the business posted $3.92 EPS. Eli Lilly and Company's revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 39.22%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, DZ Bank upgraded Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $947.39.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger acquired 117 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. This represents a 4.52% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock worth $2,894,841 over the last ninety days. Company insiders own 0.14% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.